NDA 214070 · Astrazeneca
Airsupra
Albuterol Sulfate, Budesonide · Inhalation · Corticosteroid
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jan 10, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
793
238 Phase 3, 24 recruiting
FAERS reports
1,599
319 serious, 18 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2025.
AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. ( 1 )
Mechanism: AIRSUPRA contains both albuterol and budesonide; therefore, the mechanisms of action described below for the individual components apply to AIRSUPRA. These drugs represent two classes of medications (a short-acting selective beta 2 -adrenergic agonist and a synthetic corticosteroid) that have different effects on clinical, physiological, and inflammatory indices of asthma. Albuterol In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 15, 2025 Supplement 1 · Efficacy LabelLabelLetter
- Jan 10, 2023 Original approval · Type 4 - New Combination LetterLabelReview
1 products under this application
- AIRSUPRA · ALBUTEROL SULFATE EQ 0.09MG BASE/INH; BUDESONIDE 0.08MG/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With AsthmaPivotal-lookingCompleted
Bond Avillion 2 Development LPIndustry
NCT03769090 · 3,132 participants · Start Dec 13, 2018 · Primary completion Aug 19, 2021
Drug: Albuterol sulfate metered-dose inhaler 180 μg · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 345 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device delivery system issue422
- product dose omission issue261
- asthma197
- dyspnoea183
- device malfunction179
- wrong technique in device usage process168
- drug ineffective137
- wrong technique in product usage process134
- incorrect dose administered by device130
- device use issue128
- cough110
- incorrect dose administered95
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 14 |
| 2024 | 208 |
| 2025 | 784 |
| 2026 | 581 |
Recalls
1 FDA enforcement reports for this application.
May 14, 2025 · Class II · Ongoing
Defective delivery system
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Airsupra (Albuterol Sulfate/Budesonide)
2024 spending
$24.8M
Beneficiaries
25,835
46,082 claims
Per beneficiary
$961
$43.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $925,019 |
| 2024 | $24,827,278 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- As-Needed Albuterol-Budesonide in Mild Asthma.
LaForce C, Albers F, Danilewicz A, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Papi A, Chipps BE, Beasley R, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis.
Payares-Salamanca L, Contreras-Arrieta S, Florez-García V, et al. · Pediatr Pulmonol 2020 · Comparative Study, Meta-Analysis
- Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial.
Chipps BE, Israel E, Beasley R, et al. · Chest 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Science and evidence: separating fact from fiction.
Hess DR · Respir Care 2013 · Meta-Analysis, Systematic Review
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.